Company Filing History:
Years Active: 2001
Title: Masabumi Shibuya: Innovator in VEGF Inhibition
Introduction
Masabumi Shibuya is a notable inventor based in Saitama, Japan. He has made significant contributions to the field of biotechnology, particularly in the development of therapeutic agents targeting vascular endothelial growth factor (VEGF). His work is crucial for advancing treatments for diseases associated with neovascularization.
Latest Patents
Shibuya holds a patent for a VEGF-binding polypeptide. The objective of this invention is to provide a low molecular weight VEGF inhibitor that can be utilized to treat diseases accompanying neovascularization, such as solid tumors. His research revealed that a polypeptide containing immunoglobulin-like domain 1 and immunoglobulin-like domain 2, but lacking immunoglobulin-like domain 6 and immunoglobulin-like domain 7 of the extracellular domain of the VEGF receptor FLT, possesses VEGF inhibitory activity. This innovation represents a significant advancement in the treatment of various cancers.
Career Highlights
Masabumi Shibuya is associated with Toagosei Company, Ltd., where he continues to contribute to research and development in the field of biotechnology. His expertise and innovative approach have positioned him as a key figure in his organization.
Collaborations
Shibuya has collaborated with notable colleagues, including Masaji Okamoto and Mikio Niwa. These partnerships have fostered a collaborative environment that enhances the research and development process.
Conclusion
Masabumi Shibuya's work in VEGF inhibition exemplifies the impact of innovative research in biotechnology. His contributions are paving the way for new therapeutic options in the treatment of diseases related to neovascularization.